What are the recommended procedures and precautions for performing sclerotherapy?

Sclerotherapy Procedures and Precautions

Sclerotherapy should be performed using ultrasound-guided injection of liquid or foamed sclerosing agents (polidocanol or sodium tetradecyl sulfate) into target veins, with mandatory post-treatment compression therapy, and is most appropriate for small-to-medium varicose veins (1-5 mm), reticular veins, and telangiectasias. 1

Pre-Procedure Assessment and Patient Selection

Absolute Contraindications (Do Not Proceed)

• Known hypersensitivity to sclerosing agents
• Acute venous thromboembolism (VTE)
• Severe neurological or cardiac adverse events from previous sclerotherapy
• Severe acute systemic illness or active infection
• Critical limb ischemia 2

Relative Contraindications (Proceed with Caution if Benefits Outweigh Risks)

• Pregnancy, postpartum period, and breastfeeding
• Hypercoagulable states with VTE risk
• Poorly controlled chronic systemic illness
• Risk factors for neurological or cardiac adverse events 2

Required Pre-Procedure Imaging

Perform US duplex Doppler of the lower extremity for initial diagnosis and treatment planning of varicose veins 3. This identifies the extent of venous reflux and guides appropriate vessel selection.

Procedural Technique

Equipment and Setup

• Use 3-ml Luer-Lok syringes with 30-gauge needles for small vessels 4
• Ensure excellent illumination and consider 2-3X magnification for tiny vessels 4
• Liberal alcohol preparation on skin to enhance vessel visibility 4
• Ultrasound guidance for all but the smallest superficial vessels 1

Injection Technique

• Thread the needle carefully into the vessel lumen under direct visualization or ultrasound guidance
• Inject slowly and steadily with light, controlled pressure 4
• Use liquid or foamed sclerosing agent depending on vessel size:
  • Liquid for telangiectasias and very small vessels
  • Foam for larger varicose veins (increases surface area contact with vessel wall) 3

Sclerosing Agents

The two primary agents licensed in most countries are:

• Polidocanol (Varithena) - concentrations 0.25-1.0% 1, 5
• Sodium tetradecyl sulfate (Sotradecol) 1, 5
• Hypertonic saline 18-25% (alternative) 4

No evidence demonstrates superiority of any agent over others in terms of effectiveness or patient satisfaction 1. Choose based on availability and patient factors.

Volume Limitations

Avoid high volumes of sclerosant foam - higher volumes are associated with local and distant thrombotic complications including deep vein thrombosis 6. Keep volumes conservative and within established safety parameters.

Mandatory Post-Procedure Measures

Compression Therapy

Always provide post-treatment compression - this is non-negotiable for optimal outcomes 3, 4:

• Apply cotton balls and tape immediately over injection sites
• 20-30 mm Hg elastic compression stockings with gradient decreasing pressure from distal to proximal 1
• Patients should ambulate immediately after the procedure 1
• Duration of compression varies but typically several days to weeks

Immediate Post-Procedure

• Patients can walk immediately after the procedure 1
• Same-day discharge is standard 1
• Rapid return to work and activities is expected 1

Complications and Risk Mitigation

Common Complications (Manage Expectantly)

• Pigmentation (10-30%) - residual hemosiderin deposition, usually temporary 6
• Telangiectatic matting (15-24%) - new fine vessels, often resolves spontaneously 6
• Superficial venous thrombosis (4.4%) 6

Serious Complications (Rare but Important)

• Deep vein thrombosis (1-3%) - higher risk with excessive foam volumes 6
• Stroke (0.01%) - associated with patent foramen ovale and right-to-left shunts 6
• Tissue necrosis - variable frequency, avoid extravasation 6
• Nerve damage (0.2%) - much lower than thermal ablation (7%) 1, 6
• Anaphylactic/anaphylactoid reactions - very rare 6

Key Risk Mitigation Strategies

• Screen for patent foramen ovale in patients at risk for embolic complications 6
• Use appropriate imaging to ensure accurate needle placement 2
• Maintain adequate training in duplex ultrasound and procedural phlebology 2
• Ensure proper post-treatment compression compliance 2
• Organize appropriate follow-up 2

Clinical Context and Positioning

When Sclerotherapy is Most Appropriate

According to 2023 ACR guidelines, compression sclerotherapy is usually appropriate for:

• Treatment of varicose veins (complementary with other procedures) 3
• Treatment of venous leg ulcers (equivalent alternative to other modalities) 3
• Small (1-3 mm) and medium (3-5 mm) veins 1
• Recurrent varicose veins after surgery 1

Comparative Effectiveness

Sclerotherapy has inferior long-term outcomes compared to endovenous laser ablation (EVLA) at 1-, 5-, and 8-year follow-ups, with:

• Occlusion rates of 72-89% at 1 year (versus 91-100% for EVLA) 3
• Higher rates of recurrent great saphenous vein reflux 3
• Higher saphenofemoral junction failure rates 3

However, sclerotherapy offers distinct advantages:

• No thermal injury risk to skin, nerves, muscles, or non-target vessels 3
• No tumescent anesthesia required 3
• Excellent for vessels too small for thermal ablation
• Lower procedural complexity

Common Pitfalls to Avoid

1. Proceeding without ultrasound assessment - Always confirm venous anatomy and reflux patterns
2. Using excessive foam volumes - Directly linked to thrombotic complications
3. Inadequate post-procedure compression - Essential for optimal vessel closure and preventing complications
4. Treating patients with absolute contraindications - Screen carefully for acute VTE, severe systemic illness
5. Failing to identify patent foramen ovale in patients at risk for paradoxical embolism
6. Extravasation of sclerosant - Can cause tissue necrosis; ensure proper needle placement
7. Not discussing realistic expectations - Pigmentation and matting are common and usually temporary